

Oncology Drugs Industry Research Report 2023

https://marketpublishers.com/r/O91FAD62A02DEN.html

Date: August 2023

Pages: 113

Price: US\$ 2,950.00 (Single User License)

ID: O91FAD62A02DEN

Abstracts

This report aims to provide a comprehensive presentation of the global market for Oncology Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Drugs.

The Oncology Drugs market size, estimations, and forecasts are provided in terms of and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Oncology Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Oncology Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by



Roche

these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer



Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Product Type Insights
Global markets are presented by Oncology Drugs type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Oncology Drugs are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Oncology Drugs segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others

Application Insights



This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).

This report also outlines the market trends of each segment and consumer behaviors impacting the Oncology Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Oncology Drugs market.

Oncology Drugs Segment by Application

Blood Cancer

Breast Cancer

Gastrointestinal Cancer

Prostate Cancer

Respiratory or Lung Cancer

Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America



	United States
	Canada
Europ	e
	Germany
	France
	UK
	Italy
	Russia
	Nordic Countries
	Rest of Europe
Asia-F	acific
Asia-F	Pacific China
Asia-F	
Asia-F	China
Asia-F	China Japan
Asia-F	China Japan South Korea
Asia-F	China Japan South Korea Southeast Asia
Asia-F	China Japan South Korea Southeast Asia India

Latin America



	Mexico
	Brazil
	Rest of Latin America
Middle	East & Africa
	Turkey
	Saudi Arabia
	UAE
	Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Oncology Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Drugs market, and



introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Oncology Drugs industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Drugs.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering



the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Oncology Drugs companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.



Contents

1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Oncology Drugs by Type
 - 2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
 - 1.2.2 Chemotherapy
 - 1.2.3 Targeted Therapy
 - 1.2.4 Immunotherapy (Biologic Therapy)
 - 1.2.5 Hormonal Therapy
 - 1.2.6 Others
- 2.3 Oncology Drugs by Application
 - 2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
 - 2.3.2 Blood Cancer
 - 2.3.3 Breast Cancer
 - 2.3.4 Gastrointestinal Cancer
 - 2.3.5 Prostate Cancer
 - 2.3.6 Respiratory or Lung Cancer
 - 2.3.7 Others
- 2.4 Assumptions and Limitations

3 ONCOLOGY DRUGS BREAKDOWN DATA BY TYPE

- 3.1 Global Oncology Drugs Historic Market Size by Type (2018-2023)
- 3.2 Global Oncology Drugs Forecasted Market Size by Type (2023-2028)

4 ONCOLOGY DRUGS BREAKDOWN DATA BY APPLICATION



- 4.1 Global Oncology Drugs Historic Market Size by Application (2018-2023)
- 4.2 Global Oncology Drugs Forecasted Market Size by Application (2018-2023)

5 GLOBAL GROWTH TRENDS

- 5.1 Global Oncology Drugs Market Perspective (2018-2029)
- 5.2 Global Oncology Drugs Growth Trends by Region
 - 5.2.1 Global Oncology Drugs Market Size by Region: 2018 VS 2022 VS 2029
 - 5.2.2 Oncology Drugs Historic Market Size by Region (2018-2023)
 - 5.2.3 Oncology Drugs Forecasted Market Size by Region (2024-2029)
- 5.3 Oncology Drugs Market Dynamics
 - 5.3.1 Oncology Drugs Industry Trends
 - 5.3.2 Oncology Drugs Market Drivers
 - 5.3.3 Oncology Drugs Market Challenges
 - 5.3.4 Oncology Drugs Market Restraints

6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS

- 6.1 Global Top Oncology Drugs Players by Revenue
 - 6.1.1 Global Top Oncology Drugs Players by Revenue (2018-2023)
 - 6.1.2 Global Oncology Drugs Revenue Market Share by Players (2018-2023)
- 6.2 Global Oncology Drugs Industry Players Ranking, 2021 VS 2022 VS 2023
- 6.3 Global Key Players of Oncology Drugs Head office and Area Served
- 6.4 Global Oncology Drugs Players, Product Type & Application
- 6.5 Global Oncology Drugs Players, Date of Enter into This Industry
- 6.6 Global Oncology Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition

7 NORTH AMERICA

- 7.1 North America Oncology Drugs Market Size (2018-2029)
- 7.2 North America Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 7.3 North America Oncology Drugs Market Size by Country (2018-2023)
- 7.4 North America Oncology Drugs Market Size by Country (2024-2029)
- 7.5 United States
- 7.6 Canada

8 EUROPE



- 8.1 Europe Oncology Drugs Market Size (2018-2029)
- 8.2 Europe Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 8.3 Europe Oncology Drugs Market Size by Country (2018-2023)
- 8.4 Europe Oncology Drugs Market Size by Country (2024-2029)
- 7.4 Germany
- 7.5 France
- 7.6 U.K.
- 7.7 Italy
- 7.8 Russia
- 7.9 Nordic Countries

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Oncology Drugs Market Size (2018-2029)
- 9.2 Asia-Pacific Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 9.3 Asia-Pacific Oncology Drugs Market Size by Country (2018-2023)
- 9.4 Asia-Pacific Oncology Drugs Market Size by Country (2024-2029)
- 8.4 China
- 8.5 Japan
- 8.6 South Korea
- 8.7 Southeast Asia
- 8.8 India
- 8.9 Australia

10 LATIN AMERICA

- 10.1 Latin America Oncology Drugs Market Size (2018-2029)
- 10.2 Latin America Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 10.3 Latin America Oncology Drugs Market Size by Country (2018-2023)
- 10.4 Latin America Oncology Drugs Market Size by Country (2024-2029)
- 9.4 Mexico
- 9.5 Brazil

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Oncology Drugs Market Size (2018-2029)



- 11.2 Middle East & Africa Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 11.3 Middle East & Africa Oncology Drugs Market Size by Country (2018-2023)
- 11.4 Middle East & Africa Oncology Drugs Market Size by Country (2024-2029)
- 10.4 Turkey
- 10.5 Saudi Arabia
- 10.6 UAE

12 PLAYERS PROFILED

- 11.1 Roche
 - 11.1.1 Roche Company Detail
 - 11.1.2 Roche Business Overview
 - 11.1.3 Roche Oncology Drugs Introduction
 - 11.1.4 Roche Revenue in Oncology Drugs Business (2017-2022)
- 11.1.5 Roche Recent Development
- 11.2 Celgene
- 11.2.1 Celgene Company Detail
- 11.2.2 Celgene Business Overview
- 11.2.3 Celgene Oncology Drugs Introduction
- 11.2.4 Celgene Revenue in Oncology Drugs Business (2017-2022)
- 11.2.5 Celgene Recent Development
- 11.3 Novartis
 - 11.3.1 Novartis Company Detail
 - 11.3.2 Novartis Business Overview
 - 11.3.3 Novartis Oncology Drugs Introduction
 - 11.3.4 Novartis Revenue in Oncology Drugs Business (2017-2022)
 - 11.3.5 Novartis Recent Development
- 11.4 Bristol-Myers Squibb
 - 11.4.1 Bristol-Myers Squibb Company Detail
 - 11.4.2 Bristol-Myers Squibb Business Overview
 - 11.4.3 Bristol-Myers Squibb Oncology Drugs Introduction
 - 11.4.4 Bristol-Myers Squibb Revenue in Oncology Drugs Business (2017-2022)
 - 11.4.5 Bristol-Myers Squibb Recent Development
- 11.5 Johnson & Johnson
 - 11.5.1 Johnson & Johnson Company Detail
 - 11.5.2 Johnson & Johnson Business Overview
 - 11.5.3 Johnson & Johnson Oncology Drugs Introduction
 - 11.5.4 Johnson & Johnson Revenue in Oncology Drugs Business (2017-2022)



- 11.5.5 Johnson & Johnson Recent Development
- 11.6 Merck & Co.
 - 11.6.1 Merck & Co. Company Detail
 - 11.6.2 Merck & Co. Business Overview
 - 11.6.3 Merck & Co. Oncology Drugs Introduction
 - 11.6.4 Merck & Co. Revenue in Oncology Drugs Business (2017-2022)
- 11.6.5 Merck & Co. Recent Development
- 11.7 AstraZeneca
 - 11.7.1 AstraZeneca Company Detail
 - 11.7.2 AstraZeneca Business Overview
 - 11.7.3 AstraZeneca Oncology Drugs Introduction
 - 11.7.4 AstraZeneca Revenue in Oncology Drugs Business (2017-2022)
 - 11.7.5 AstraZeneca Recent Development
- 11.8 Pfizer
 - 11.8.1 Pfizer Company Detail
 - 11.8.2 Pfizer Business Overview
 - 11.8.3 Pfizer Oncology Drugs Introduction
 - 11.8.4 Pfizer Revenue in Oncology Drugs Business (2017-2022)
 - 11.8.5 Pfizer Recent Development
- 11.9 Amgen
 - 11.9.1 Amgen Company Detail
 - 11.9.2 Amgen Business Overview
 - 11.9.3 Amgen Oncology Drugs Introduction
 - 11.9.4 Amgen Revenue in Oncology Drugs Business (2017-2022)
 - 11.9.5 Amgen Recent Development
- 11.10 Eli Lilly
- 11.10.1 Eli Lilly Company Detail
- 11.10.2 Eli Lilly Business Overview
- 11.10.3 Eli Lilly Oncology Drugs Introduction
- 11.10.4 Eli Lilly Revenue in Oncology Drugs Business (2017-2022)
- 11.10.5 Eli Lilly Recent Development
- 11.11 AbbVie
 - 11.11.1 AbbVie Company Detail
 - 11.11.2 AbbVie Business Overview
 - 11.11.3 AbbVie Oncology Drugs Introduction
 - 11.11.4 AbbVie Revenue in Oncology Drugs Business (2017-2022)
 - 11.11.5 AbbVie Recent Development
- 11.12 Takeda
- 11.12.1 Takeda Company Detail



- 11.12.2 Takeda Business Overview
- 11.12.3 Takeda Oncology Drugs Introduction
- 11.12.4 Takeda Revenue in Oncology Drugs Business (2017-2022)
- 11.12.5 Takeda Recent Development
- 11.13 Astellas
 - 11.13.1 Astellas Company Detail
 - 11.13.2 Astellas Business Overview
 - 11.13.3 Astellas Oncology Drugs Introduction
 - 11.13.4 Astellas Revenue in Oncology Drugs Business (2017-2022)
 - 11.13.5 Astellas Recent Development
- 11.14 lpsen
 - 11.14.1 Ipsen Company Detail
- 11.14.2 Ipsen Business Overview
- 11.14.3 Ipsen Oncology Drugs Introduction
- 11.14.4 Ipsen Revenue in Oncology Drugs Business (2017-2022)
- 11.14.5 Ipsen Recent Development
- 11.15 Sanofi
 - 11.15.1 Sanofi Company Detail
 - 11.15.2 Sanofi Business Overview
 - 11.15.3 Sanofi Oncology Drugs Introduction
 - 11.15.4 Sanofi Revenue in Oncology Drugs Business (2017-2022)
 - 11.15.5 Sanofi Recent Development
- 11.16 Bayer
 - 11.16.1 Bayer Company Detail
 - 11.16.2 Bayer Business Overview
 - 11.16.3 Bayer Oncology Drugs Introduction
 - 11.16.4 Bayer Revenue in Oncology Drugs Business (2017-2022)
 - 11.16.5 Bayer Recent Development
- 11.17 Biogen Idec
 - 11.17.1 Biogen Idec Company Detail
 - 11.17.2 Biogen Idec Business Overview
 - 11.17.3 Biogen Idec Oncology Drugs Introduction
 - 11.17.4 Biogen Idec Revenue in Oncology Drugs Business (2017-2022)
 - 11.17.5 Biogen Idec Recent Development
- 11.18 Teva
 - 11.18.1 Teva Company Detail
 - 11.18.2 Teva Business Overview
 - 11.18.3 Teva Oncology Drugs Introduction
 - 11.18.4 Teva Revenue in Oncology Drugs Business (2017-2022)



11.18.5 Teva Recent Development

11.19 Otsuka

- 11.19.1 Otsuka Company Detail
- 11.19.2 Otsuka Business Overview
- 11.19.3 Otsuka Oncology Drugs Introduction
- 11.19.4 Otsuka Revenue in Oncology Drugs Business (2017-2022)
- 11.19.5 Otsuka Recent Development

11.20 Eisai

- 11.20.1 Eisai Company Detail
- 11.20.2 Eisai Business Overview
- 11.20.3 Eisai Oncology Drugs Introduction
- 11.20.4 Eisai Revenue in Oncology Drugs Business (2017-2022)
- 11.20.5 Eisai Recent Development

11.21 Merck KGaA

- 11.21.1 Merck KGaA Company Detail
- 11.21.2 Merck KGaA Business Overview
- 11.21.3 Merck KGaA Oncology Drugs Introduction
- 11.21.4 Merck KGaA Revenue in Oncology Drugs Business (2017-2022)
- 11.21.5 Merck KGaA Recent Development

11.22 Gilead Sciences

- 11.22.1 Gilead Sciences Company Detail
- 11.22.2 Gilead Sciences Business Overview
- 11.22.3 Gilead Sciences Oncology Drugs Introduction
- 11.22.4 Gilead Sciences Revenue in Oncology Drugs Business (2017-2022)
- 11.22.5 Gilead Sciences Recent Development

13 REPORT CONCLUSION

14 DISCLAIMER



I would like to order

Product name: Oncology Drugs Industry Research Report 2023

Product link: https://marketpublishers.com/r/O91FAD62A02DEN.html

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/O91FAD62A02DEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970